e-learning
resources
Stockholm 2007
Monday 17.09.2007
Clinical aspects of pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
P. Kabunga, C. Handler, C. Das, S. Reddecliffe, C. Denton, C. Black, H. Penn, J. G. Coghlan, J. Davar (London, United Kingdom)
Source:
Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Session:
Clinical aspects of pulmonary arterial hypertension
Session type:
Oral Presentation
Number:
1592
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kabunga, C. Handler, C. Das, S. Reddecliffe, C. Denton, C. Black, H. Penn, J. G. Coghlan, J. Davar (London, United Kingdom). Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival. Eur Respir J 2007; 30: Suppl. 51, 1592
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Imaging of complicated pneumonia: what is new?
Related content which might interest you:
Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Identifying early pulmonary arterial hypertension in patients with systemic sclerosis
Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018
Year: 2018
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Screening for pulmonary arterial hypertension in systemic sclerosis
Source: Eur Respir Rev 2009; 18: 162-169
Year: 2009
Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis
Source: Eur Respir J 2007; 30: Suppl. 51, 344s
Year: 2007
Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening
Source: Eur Respir Rev 2011; 20: 270-276
Year: 2011
Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Source: Eur Respir Rev 2009; 18: 253-259
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept